Dosage (total number of 20 minutes, twice daily 20 minutes twice a day for 135 days for 12 weeks sessions) Primary Outcome PTSD (PCL-C; PTSD (CAPS, PCL-M) (Measure(s)) administered in Swahili, French, Lingala, and English). Secondary Outcome None assessed - Depression (BDI) - Domain (Measure(s)) Quality of life (Q-LES-Q) Total Sample Size N=42 N=5 n=21 n=5 Participants: Intervention Participants: Comparison n=21 N/A 1 This case control study documented a clinically significant change reduction in PTSD symptom severity among the TM group over the course of the intervention. Differences in the PCL-C scores between the TM and delayed intervention group were also found to be statistically significant. The maintenance of these changes was not examined at follow up. Study 2 This case series found a reduction in PTSD symptom severity over the course of the intervention on both self-report and clinical interviews. This was also seen with a significant reduction in depression scores, and an increase in quality of life scores over the period of the intervention. It was noted that one veteran reported worsened scores on the BDI at 8 weeks, than at baseline, but this may have been explained by changes to medication. Outcome measures were not used at follow up, and it is not known if the symptom changes were maintained.
Dosage (total number of sessions) 20 minutes, twice daily for 135 days 20 minutes twice a day for 12 weeks Primary Outcome (Measure(s)) PTSD (PCL-C; administered in Swahili, French, Lingala, and English). PTSD (CAPS, PCL-M) Secondary Outcome Domain (Measure(s)) None assessed - Depression (BDI) - Quality of life (Q-LES-Q) Total Sample Size N=42 N=5 Participants: Intervention n=21 n=5 Participants: Comparison n=21 N/A 1 This case control study documented a clinically significant change reduction in PTSD symptom severity among the TM group over the course of the intervention. Differences in the PCL-C scores between the TM and delayed intervention group were also found to be statistically significant. The maintenance of these changes was not examined at follow up. Study 2 This case series found a reduction in PTSD symptom severity over the course of the intervention on both self-report and clinical interviews. This was also seen with a significant reduction in depression scores, and an increase in quality of life scores over the period of the intervention. It was noted that one veteran reported worsened scores on the BDI at 8 weeks, than at baseline, but this may have been explained by changes to medication. Outcome measures were not used at follow up, and it is not known if the symptom changes were maintained.
Question%203%20-%20PTSD%20-%20Evidence%20Profile%20November%202016.DOCX